Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
National Cancer Institute (NCI)
Gilead Sciences
Hoffmann-La Roche
AstraZeneca
Merck Sharp & Dohme LLC
Arcus Biosciences, Inc.
Wake Forest University Health Sciences
AstraZeneca
Bristol-Myers Squibb
Thomas Jefferson University
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Massachusetts General Hospital
Hoffmann-La Roche
Intergroupe Francophone de Cancerologie Thoracique
BeOne Medicines
University Hospital, Lille
Guangzhou Medical University
Montefiore Medical Center
Tianjin Medical University Cancer Institute and Hospital
Bristol-Myers Squibb
University of Pittsburgh
Dana-Farber Cancer Institute
Swiss Cancer Institute
Beijing Cancer Prevention & Treatment Society
Regeneron Pharmaceuticals
Big Ten Cancer Research Consortium
Sun Yat-sen University
University Health Network, Toronto
Shenyang Sunshine Pharmaceutical Co., LTD.
Mario Negri Institute for Pharmacological Research
Università Vita-Salute San Raffaele
CSPC Megalith Biopharmaceutical Co.,Ltd.
Mayo Clinic
Lantern Pharma Inc.
Intergroupe Francophone de Cancerologie Thoracique
Memorial Sloan Kettering Cancer Center
University of Kentucky
Sanofi
Weill Medical College of Cornell University
Bristol-Myers Squibb
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Genfleet Therapeutics (Shanghai) Inc.
Latin American Cooperative Oncology Group
Innovent Biologics (Suzhou) Co. Ltd.
Genelux Corporation
BeiGene